Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation.
In an effort to combine the benefits of fibrinolytics, such as staphylokinase (Sak), with those of thrombin inhibitors for the prevention of vessel reocclusion after vascular injury, we produced chimeric protein with plasminogen activator and thrombin-inhibiting properties. This fusion protein was a construct consisting of Sak (SakSTAR) lengthened about 36 amino acids from the C-terminus end of hirudin. We inserted 16 point mutations into the sequence of the gene encoding SakSTAR for reduced antibody binding from 50% to about 17% and inserted two RGD sequences for antiplatelet activity. The inhibition rate of platelet aggregation was 27%. Moreover, we proposed an efficient method of expression and purification in which we used 16 mg/L of anEscherichia coli strain of this novel fusion protein and retained full biologic activities toward plasminogen and thrombin.